Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics.

Christopoulos KA, Smith MB, Pareek P, Dawdani A, Erguera XA, Dance KV, Walker RS, Grochowski J, Mayorga-Munoz F, Hickey MD, Johnson MO, Sauceda J, Gutierrez JI, Montgomery ET, Colasanti JA, Collins LF, McNulty MC, Koester KA